BioAffinity Technologies, Retained Earnings Over Time
| BIAF Stock | USD 1.22 0.05 4.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioAffinity Technologies, Performance and BioAffinity Technologies, Correlation. BioAffinity |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare bioAffinity Technologies, and related stocks such as Natera Inc, Caredx Inc, and Illumina Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA | (137.5 M) | (137.5 M) | (137.5 M) | (174.7 M) | (179.8 M) | (250.1 M) | (345.8 M) | (482.2 M) | (574.5 M) | (699.2 M) | (929.3 M) | (1.4 B) | (1.9 B) | (2.4 B) | (2.3 B) |
| CDNA | (156.6 M) | (156.6 M) | (156.6 M) | (160.2 M) | (159.4 M) | (173.1 M) | (212.6 M) | (268 M) | (311.8 M) | (333.8 M) | (352.5 M) | (383.2 M) | (460.4 M) | (678.3 M) | (644.4 M) |
| ILMN | (6.7 M) | (68.7 M) | 82.5 M | 207.9 M | 561.2 M | 1 B | 1.5 B | 2.3 B | 3.1 B | 4.1 B | 4.7 B | 5.5 B | 1.1 B | (19 M) | (18.1 M) |
| TWST | (80.3 M) | (80.3 M) | (80.3 M) | (80.3 M) | (80.3 M) | (80.3 M) | (139.6 M) | (210.9 M) | (318.5 M) | (458.5 M) | (610.6 M) | (828.4 M) | (1 B) | (1.2 B) | (1.2 B) |
| A | 757 M | 5.5 B | 6.1 B | 6.5 B | 5.6 B | 6.1 B | (126 M) | (336 M) | (18 M) | 81 M | 348 M | 324 M | 782 M | 899.3 M | 854.3 M |
| TMO | 55.4 M | 6.7 B | 7.7 B | 8.8 B | 10.4 B | 12.1 B | 13.9 B | 15.9 B | 18.7 B | 22.1 B | 28.1 B | 35.4 B | 41.9 B | 47.4 B | 49.7 B |
| DHR | (111.3 M) | 13.1 B | 15.4 B | 18 B | 20.3 B | 21 B | 20.7 B | 22.8 B | 25.2 B | 24.2 B | 27.2 B | 32.8 B | 39.2 B | 41.1 B | 43.1 B |
| GH | (107.6 M) | (107.6 M) | (107.6 M) | (107.6 M) | (107.6 M) | (107.6 M) | (107.6 M) | (195.7 M) | (280.8 M) | (352.8 M) | (606.6 M) | (1 B) | (1.7 B) | (2.1 B) | (2 B) |
| CRL | 156.1 M | (465.6 M) | (368.3 M) | (265.5 M) | (138.8 M) | 10.5 M | 165.3 M | 288.7 M | 42.1 M | 280.3 M | 625.4 M | 980.8 M | 1.4 B | 1.9 B | 2 B |
| MYGN | (14.9 M) | (38.6 M) | (12.7 M) | 30.9 M | 2 M | (77 M) | (73.2 M) | (68.4 M) | 52.8 M | 25.6 M | (227 M) | (254.2 M) | (366.2 M) | (629.5 M) | (598 M) |
bioAffinity Technologies, and related stocks such as Natera Inc, Caredx Inc, and Illumina Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| bioAffinity Technologies, | BIAF |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.22
Check out BioAffinity Technologies, Performance and BioAffinity Technologies, Correlation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
BioAffinity Technologies, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.